Women diagnosed with Parkinson’s disease exhibit a higher amyloid plaque burden in the brain compared to men, according to a study led by the Mayo Clinic Arizona. While men with Parkinson’s are generally at a higher risk of developing dementia, this new research indicates that women harbor more Alzheimer’s-related protein deposits, even when adjusting for age and the APOE4 genetic risk factor.
Why do women with Parkinson’s show higher amyloid levels?
Researchers analyzed brain tissue from 230 participants in the Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Data presented at the European Academy of Neurology Congress revealed that 57% of women in the study displayed a high amyloid plaque burden, compared to 40% of men. According to the study, the mean cortical total plaque score for women reached 6.5 out of 15, while men averaged 4.9 out of 15. Neuritic plaque density followed a similar trend, measuring 1.7 out of 3 for women versus 1.3 out of 3 for men.
While amyloid-beta plaques are the hallmark of Alzheimer’s disease, Parkinson’s disease is primarily driven by the misfolding of alpha-synuclein protein into toxic deposits known as Lewy bodies.
Does higher amyloid plaque lead to worse cognitive decline?
Surprisingly, the increased amyloid burden in women does not appear to translate into cognitive differences. Erika Driver-Dunckley, MD, of the Mayo Clinic Arizona stated that both men and women in the study demonstrated similar rates of Alzheimer’s-related dementia and comparable results on cognitive testing. This finding suggests a complex relationship between protein accumulation and clinical symptoms. While men with Parkinson’s typically face a higher risk of dementia, the study suggests it is possible women have some protection from alpha-synuclein-driven decline but not from damage linked to amyloid accumulation.
What are the implications for future Parkinson’s research?
The discrepancy between physical brain pathology and observed cognitive performance highlights a need for further research. Because women with Parkinson’s live longer than men, and are more prone to amyloid buildup and Alzheimer’s disease, understanding the meaning of these results is complicated. Driver-Dunckley noted that future large-scale clinicopathological studies are required to identify the mechanisms behind these differences.
When reviewing neurodegenerative risk, clinicians should account for sex-specific biomarkers. Standardized testing may need to be adjusted if women and men process protein-related damage differently.
Frequently Asked Questions
Is high amyloid plaque a definitive sign of Alzheimer’s?
Not necessarily. While amyloid-beta aggregation is a hallmark of Alzheimer’s, this study shows that significant plaque buildup can exist in patients with Parkinson’s disease without triggering disparate cognitive results between sexes.
Do men and women experience Parkinson’s differently?
Yes. According to clinical observations, men are generally at a higher risk for developing dementia as a symptom of Parkinson’s, and women with the condition live longer than men.
How was the amyloid burden measured?
The study utilized post-mortem autopsy data from participants in the Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program to assess the density and score of amyloid plaques in the brain.
Are you interested in the latest breakthroughs in neurodegenerative health? Subscribe to our newsletter for updates on clinical research and emerging trends in neurology.